Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Travere Therapeutics reports robust earnings, eyes market expansion opportunities

Travere Therapeutics is on a solid financial footing with promising drug launches and clinical advancements. While facing regulatory and competitive challenges, the company's strategic focus on market expansion and product utilization presents significant growth opportunities. With a strong cash position and ongoing clinical developments, Travere is well-positioned for future success.

Travere Therapeutics reports strong Q1 performance amidst FILSPARI launch

Travere Therapeutics' Q1 performance was driven by strong FILSPARI sales and positive physician adoption.
Despite challenges in FSGS and HCU programs, regulatory flexibility and patient community evolution present opportunities.
Physician interest in FILSPARI data and payer coverage quality are key strengths for the successful launch.
Monitoring metrics and upcoming study readouts offer avenues for growth and optimization in rare disease treatments.

Travere Therapeutics reports strong Q2 performance and growth opportunities

Travere Therapeutics showcased strong performance with revenue growth and positive clinical results across key programs.
The company's strategic focus on core pipeline programs and divestment of non-core assets has bolstered its financial position.
Challenges include competitive dynamics, regulatory uncertainties, and the need for disciplined spending amidst growth opportunities.
Overall, Travere is well-positioned for future growth with promising pipeline programs and a focus on market expansion.

Travere Therapeutics reports strong Q3 performance and strategic advancements

Travere Therapeutics showcased strong operational and financial performance in Q3 2023, with advancements in key programs and positive regulatory engagements.
The company's strategic focus on rare disease treatments, patient education efforts, and regulatory alignment position it well for future growth.
Challenges in revenue forecasting, market positioning, and evolving treatment landscapes highlight areas for ongoing strategic focus and adaptation.
Opportunities in market expansion, revenue growth, program advancements, and patient engagement present avenues for continued success and impact.

Travere Therapeutics reports strong revenue growth and strategic advancements

Travere Therapeutics had a successful year with strong revenue growth and progress in key treatments
Filspari's performance in IgAN drove demand and revenue, positioning the company for further growth
Challenges include the DUPLEX study results and low innovation in the prescriber base
Opportunities lie in sNDA submissions, ongoing studies, and potential for full approval and broader label

Travere Therapeutics excels in Q1 with FILSPARI market success

Travere Therapeutics showcased strong performance and financial stability in Q1 2024, driven by FILSPARI's successful commercial launch and positive patient outcomes.
The company's focus on market adoption, regulatory milestones, and engagement strategies positions it for continued growth and potential inclusion in treatment guidelines.
Challenges in inventory management, regulatory compliance, and strategic alignment with stakeholders need to be addressed to capitalize on growth opportunities and maintain market leadership.

Travere Therapeutics excels in Q2 2024, poised for growth

Travere Therapeutics delivered a strong performance in Q2 2024, driven by FILSPARI's growth and positive regulatory developments.
While facing challenges in regulatory processes and market expansion, the company's solid financial position and ongoing initiatives position it well for future success.
Opportunities for growth abound through potential approvals, global expansion, and advancements in drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the close of the U.S. financial markets. Management will provide an update on the financial results and provide a business update in a webcast on February 23, 2023, at 4:30 p.m. ET.

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

There are other powerful catalysts brewing in the pipeline that would deliver leaping sales growth in the coming years. Sparsentan's Prescription Drug User Fee Act for IgAN is now rescheduled for February 17.

Travere: Multiple Catalysts Stacking

IgA Nephropathy (IgAN) is a chronic autoimmune disease that affects the kidneys and leads to end-stage kidney disease. Current treatments for IgAN are limited in their effectiveness. Sparsentan, developed by Travere Therapeutics, is an experimental drug that targets both the endothelin and angiotensin pathways involved in IgAN.

Travere: Sparsentan Approval Is Likely, But Future Is Uncertain

Reata Pharmaceuticals

These two growth stocks might deliver enormous gains for shareholders this month.

The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February

Travere Therapeutics, Inc. is set to find out on Feb 17th whether the FDA has granted accelerated approval to lead drug candidate Sparsentan. Indicated for kidney disease IgAN and FSGS, the accelerated approval would be granted based on the drug's ability to reduce proteinuria.

Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is Critical

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference, on Thursday, January 12, 2023, at 11:15 a.m. PT.

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President, Investor Relations Eric Dube - President and Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Senior Vice President of Research and Development Conference Call Participants Maurice Raycroft - Jefferies Greg Harrison - Bank of America Tim Lugo - William Blair Liisa Bayko - Evercore ISI Laura Chico - Wedbush Securities Ed Arce - H.C. Wainwright & Co. Operator Good day and welcome to the Travere Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call.

Travere Therapeutics, Inc. (TVTX) Q3 2022 Earnings Call Transcript

EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023

Travere Therapeutics Reports Third Quarter 2022 Financial Results

Data support the Company's lead investigational product candidate sparsentan Data support the Company's lead investigational product candidate sparsentan

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Travere Therapeutics to Report Third Quarter 2022 Financial Results

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Travere (TVTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Travere (TVTX) is Poised for a Turnaround After Losing 22.2% in 4 Weeks

Conference call and webcast to be held at 4:30p.m. ET

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company's ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022. Data exploring genomic population-based estimates of the incidence of HCU will also be presented. The Company is currently advancing a novel investigational enzyme replacement therapy, pegtibatinase, for the treatment of HCU.

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

ST. GALLEN, Switzerland & SAN DIEGO--(BUSINESS WIRE)--CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD). The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the

CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2021 Earnings Conference Call Aug 0, 2022 8:08 AM ET Company Participants Chris Cline - Senior Vice President, Investor Relations Eric Dube - President and Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - Chief Financial Officer William Rote - Senior Vice President of Research and Development Conference Call Participants Tim Lugo - William Blair Maurice Raycroft - Jefferies Joseph Schwartz - SVB Securities Carter Gould - Barclays Laura Chico - Wedbush Edward Nash - Canaccord Operator Good day and welcome to the Travere Therapeutics Second Quarter Financial Results and Corporate Update. Today's conference is being recorded.

Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q2 2022 Results - Earnings Call Transcript

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update.

Travere Therapeutics Reports Second Quarter 2022 Financial Results

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:00 a.m. ET.

Travere Therapeutics to Report Second Quarter 2022 Financial Results

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COVID19--Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET.

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy. Travere Therapeutics says the FDA has indicated that it is not currently planning to hold an advisory committee.

News for Travere Therapeutics Stock (TVTX)